

July 28,2020

National Stock Exchange of India Ltd  
Listing Department  
Exchange Plaza, 5th Floor, Plot No: C/1  
G - Block, Bandra - Kurla Complex  
Bandra (East)  
Mumbai – 400 051

**BSE Limited**  
**Corporate Relationship Department**  
**1st floor, New Trading Ring**  
**Rotunda Building, P J Towers**  
**Dalal Street Fort,Mumbai- 400001**

Sub:Disclosure under Regulation 23(9) of SEBI (LODR) Regulations, 2015, for the half year ended on March 31, 2020

Dear Sir/Madam

Pursuant to Regulation 23(9) of the SEBI (LODR) Regulations, 2015, we hereby submit the disclosure of Related Party transactions, on a consolidated basis for the half year ended March 31, 2020.

Kindly take the above on your records.

Thanking you

Yours faithfully

For **Orchid Pharma Limited**



Manish Dhanuka  
Managing Director



**CONSOLIDATED DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE HALF YEAR ENDED 31<sup>ST</sup> MARCH 2020**

**(i) List of parties having significant influence**

<b>Holding Company</b>	Dhanuka Laboratories Limited (w.e.f. March 31, 2020)
<b>Subsidiary Companies</b>	Orchid Europe Limited, UK Orchid Pharmaceuticals Inc., USA Orgenus Pharma Inc., USA (Subsidiary of Orchid Pharmaceuticals Inc USA.) Orchid Pharma Inc / Karalex Pharma USA, (Subsidiary of Orchid Pharmaceuticals Inc, USA) Orchid Pharmaceuticals SA (Proprietary) Limited, South Africa Bexel Pharmaceuticals Inc., USA Diakron Pharmaceuticals Inc., USA
<b>Key Management Personnel and their relatives</b>	
Mr. Ram Gopal Agarwal *	Chairman and Non - executive director (w.e.f. June 29, 2020)
Mr. Manish Dhanuka *	Managing Director (w.e.f. June 29, 2020)
Mr. Mridul Dhanuka *	Wholetime Director (w.e.f. June 29, 2020)
Mr. Arun Kumar Dhanuka	Non Executive Director (w.e.f. March 31, 2020)
Mr. K. Raghavendra Rao	Managing Director (till December 31, 2019)
Mr. L. Chandrasekar	Chief Financial Officer (till June 30, 2019)
Mr. Sunil Kumar Gupta	Chief Financial Officer (w.e.f. June 29, 2020)
Ms. Nikita K	Company Secretary (w.e.f. March 05, 2020)
* Joined the Board as Directors effective from March 31, 2020	
<b>Enterprises in which Key Management Personnel and their Relatives have significant influence</b>	Orchid Healthcare Private Ltd. (till December 31, 2019)

*Manish Dhanuka*



*S. K. S. M.*



**b) Transactions during the period 01.10.2019 to 31.03.2020**

Amount (Rs.in Lakhs)			
S.No.	Nature of transactions	H2 FY 2019-20	H1 FY 2019-20
1	Short Term Borrowings / Advances received (Dhanuka Laboratories Ltd)	12.04	-
2	Unsecured advance Orchid Pharma Inc.	-	52.94
3	Sale of goods Orchid Pharma Inc.	129.76	351.85
4	Availment of services/ reimbursement Orchid Europe Limited	49.32	38.11
5	Remuneration and contribution to funds**		
	K. Raghavendra Rao	0.95	10.25
	L. Chandrasekar*	-	13.69
	Nikita K	0.46	-

\*Retired from Service on 30/06/2019

\*Postemployment benefit comprising compensated absences is not disclosed as these are determined for the Company as a whole.

*M. Hamid*



*S. K. Srinivas*

**c) Balances at the end of the year**

S.No.	Nature of transactions	Amount (Rs.in Lakhs)	
		As at Mar 31, 2020	As at Sep 30, 2019
1	Trade receivables ** Orchid Pharma Inc.	2,830.05	2,526.88
2	Loans and advances (Current) * Bexel Pharmaceuticals Inc., USA Diakron Pharmaceuticals Inc., USA Orchid Pharma Inc.	- - -	3,585.47 3.28 1,640.61
3	Short term borrowings Orchid Healthcare Private Ltd.	-	3,216.77
4	Trade payables Orchid Europe Limited Bexel Pharmaceuticals Inc., USA Orgenus Pharma Inc., USA	31.12 - -	24.91 274.05 71.74

\* Provision has been made for the entire outstanding amount during the Year

For Orchid Pharma Limited



**Manish Dhanuka**  
 Managing Director



For Orchid Pharma Limited



**Sunil Kumar Gupta**  
 Chief Financial Officer